Patrick Murray joins BD Diagnostics
SPARKS, Md. — A global medical technology company has appointed a worldwide director of scientific affairs for its diagnostic systems division.
Becton, Dickinson and Co. said that Patrick Murray has joined its BD Diagnostics segment. In his new role, Murray "will leverage his clinical expertise to best define new product requirements, evaluate new technologies and engage external experts and institutions in BD’s innovation process," the company said.
Prior to joining BD, Murray served as chief of the microbiology service and senior scientist at the National Institutes of Health Clinical Center.
Study finds that low body fat may not reduce risk of diabetes, heart disease
BOSTON — People with lower percentages of body fat are not necessarily at lower risk for diabetes and heart disease, according to a new international study.
The study identified a gene that is linked with having less body fat but also with having an increased risk of Type 2 diabetes and heart disease. The investigators examined the genomes of more than 75,000 people and found that the gene, IRS1, was linked to less body fat, but also to unhealthy levels of cholesterol and blood glucose.
“We’ve uncovered a truly fascinating genetic story. … When we found the effect of this gene, we were very intrigued by the unexpected finding,” said study researcher Douglas Kiel, a professor at the Harvard Medical School and researcher at the Institute for Aging Research at HMS affiliate Hebrew SeniorLife. “People, particularly men, with a specific form of the gene are both more likely to have lower percent body fat [and] to develop heart disease and Type 2 diabetes. In simple terms, it is not only overweight individuals who can be predisposed for these metabolic diseases.”
MannKind: Patients have better view of insulin therapy when using Afrezza
SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.
MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.
“The challenge of diabetes and its treatment can have a profound psychosocial impact on the patient, which must be addressed as part of managing the condition,” lead study investigator and Johns Hopkins University School of Medicine professor Richard Rubin said. “Current mealtime insulin therapy regimens require patients to titrate their insulin and use injections, both of which can negatively affect their perceptions of therapy and their long-term compliance.”